Clinical trials
Pharmacodynamics clinical trials
Below are recruiting pharmacodynamics clinical trials, each written for real people, not researchers. We’re tracking 166 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07289763RecruitingPhase 2
Study of SHR-2173 for primary membranous nephropathy
This trial tests an investigational drug called SHR-2173 for people with primary membranous nephropathy, a kidney disease that causes protein leakage. The study aims to see if the drug is safe and effective, and it involves periodic injections and monitoring.
Nanjing, JiangsuAges 18–75 - NCT07201467RecruitingPhase 1/Phase 2
KN060 for dialysis patients with kidney failure
This study tests an experimental drug called KN060, given to people with end-stage kidney disease on dialysis, to see if it is safe and helps with blood clotting. It may be an option if you are on stable dialysis and not at high risk for bleeding.
Beijing, Beijing MunicipalityAges 18–80 - NCT07614477RecruitingPhase 2
Testing EVER001 for kidney protein-loss diseases
This study tests a new drug called EVER001 to see if it can reduce protein loss in urine and improve kidney function in patients with specific kidney diseases (FSGS, MCD, or IgAN). These are autoimmune kidney conditions that cause the kidneys to leak protein into the urine.
Beijing, Beijing MunicipalityAges 18–75 - NCT07179640RecruitingPhase 1/Phase 2
Testing ALE1 for hypophosphatasia in healthy people and patients
This trial tests a new medicine called ALE1 for hypophosphatasia (HPP), a rare bone condition. It first checks safety in healthy volunteers, then tests if the medicine helps people with HPP.
WürzburgAges 18–50 - NCT07738991RecruitingPhase 1
Study of NKF-PEG compared to Neulasta in healthy men
This study tests a new medicine called NKF-PEG, which is similar to Neulasta (a drug that helps boost white blood cells after chemotherapy). It is being tested in healthy men to see how the body processes it and to check for side effects.
ZhengzhouAges 18–55 - NCT07448038RecruitingPhase 2
Study of selnoflast for heart artery inflammation
This trial tests a drug called selnoflast to see if it can reduce inflammation in the arteries of people with atherosclerosis (hardening of the arteries) who are at risk for heart attacks or other serious heart problems.
Beverly Hills, CaliforniaAges 18–80 - NCT07559136RecruitingPhase 1
Safety study of HRS9531 injection for teen obesity
This study tests whether a new injectable medication called HRS9531 is safe and well-tolerated in teenagers aged 12–17 with obesity. Researchers will monitor how your body handles the medication and whether it affects your weight.
Wuhan, HubeiAges 12–18 - NCT07610278RecruitingPhase 2
Blood Pressure and Cholesterol Treatment Study
This study tests a combination of two new medications (QCZ484 and inclisiran) designed to lower both blood pressure and cholesterol levels. You may be a good fit if you have high blood pressure and high cholesterol that isn't fully controlled by current treatments.
Foley, AlabamaAges 18–75 - NCT07234942RecruitingPhase 1
Safety study of RO7812653 for early Alzheimer's disease
This trial tests a new drug, RO7812653, in people with early symptomatic Alzheimer's disease (including mild cognitive impairment due to AD). The goal is to see if it is safe and how the body handles it.
Toronto, OntarioAges 50–75 - NCT07702890RecruitingPhase 1/Phase 2
Testing a new drug for obesity and type 2 diabetes
This trial tests an investigational drug called GUB-UCN2 in people who are healthy, overweight, or have type 2 diabetes. The goal is to see if the drug is safe and how the body processes it.
NeussAges 18–75 - NCT07271693RecruitingPhase 1
Safety study of a new medicine in healthy volunteers
This trial tests a new medicine called RO7806881 in healthy volunteers to see if it is safe, what dose is best, and how the body handles it. It is an early study that helps researchers decide if the drug should be tested in people with a disease.
ChristchurchAges 18–50 - NCT07721597RecruitingEarly Phase 1
Testing ZP6590 in Men of Various Weights
This trial tests an experimental medication called ZP6590 given as injections. It's for men who are at a normal weight, overweight, or have obesity, and studies how safe and well-tolerated the drug is in different doses.
Neuss, North Rhine-WestphaliaAges 18–60 - NCT07717905RecruitingPhase 1/Phase 2
Testing BBT001 for chronic hives
This trial tests a new medicine called BBT001 for people with chronic spontaneous urticaria (long-lasting hives without a known cause). It aims to see if the drug is safe and helps reduce itching and hives.
Wuhu, AnhuiAges 18–75 - NCT07282574RecruitingPhase 2
Testing a new study drug for progressive MS
This trial tests a new study drug added to your current MS treatment (ocrelizumab) for people with progressive MS. It aims to see if the combination works better than ocrelizumab alone.
Kogarah, New South WalesAges 18–60 - NCT07567872RecruitingPhase 1
Inhaled HRS-9821 Safety Study in Healthy People and COPD Patients
This is an early-stage study testing a new inhaled medication (HRS-9821) to see if it is safe and how the body processes it. Researchers will first test it in healthy volunteers, then in people with COPD (chronic lung disease) to understand if it might help with breathing.
Chengdu, SichuanAges 18–75 - NCT04216342RecruitingPhase 1
Testing a new breathing-drug ingredient in healthy adults
This early study (Phase 1) tests how safe and tolerable Fx-5A is, and how the body processes it, in healthy volunteers. It’s mainly looking to understand side effects and drug levels rather than treating a disease.
Bethesda, MarylandAges 18–99 - NCT03708900RecruitingPhase 2
Osilodrostat study for children with Cushing’s syndrome
This Phase 2 study tests how osilodrostat works in children and teens with Cushing’s syndrome—what the drug does in the body, how it affects hormones, and how safely it’s tolerated. It may help families who cannot have immediate surgery or whose surgery has already failed or is still pending.
San Francisco, CaliforniaAges 2–17 - NCT03850574RecruitingPhase 1/Phase 2
Tuspetinib for relapsed or hard-to-treat AML
This early-phase study tests tuspetinib in people with AML that has come back or did not respond to treatment. The goal is to learn whether it is safe and tolerable, how the drug behaves in the body, and whether it shows signs of benefit.
Birmingham, AlabamaAges 18 years+ - NCT04278404Recruiting
Drug safety study for children already on certain medicines
This study measures how certain medicines move through the body and checks their safety in children. It may help doctors better understand dosing and side effects in kids who are already receiving these treatments, or in some kids who recently tested positive for COVID-19.
Phoenix, ArizonaAges birth–20 years - NCT04833894RecruitingPhase 2/Phase 3
Efgartigimod for children with generalized myasthenia gravis
This trial studies how efgartigimod (given through a vein) behaves in children and whether it is safe and effective for generalized myasthenia gravis. It is designed for children who have not done well enough with standard treatments like steroids or other immune medicines.
Chicago, IllinoisAges 2–18 - NCT07378644RecruitingPhase 2/Phase 3
Testing SKY-0515 for Huntington's disease
This trial tests a new drug called SKY-0515 in people with Huntington's disease. The goal is to see if it can safely improve symptoms or slow the disease down.
Buenos Aires, Buenos AiresAges 25 years+ - NCT05041907RecruitingPhase 2
Testing an antiviral’s effects in early COVID-19
This trial looks at how well an antiviral works in the body when started early in people with COVID-19 symptoms. You may be able to join if you’re an otherwise healthy adult with confirmed infection and symptoms for less than 4 days.
Minas GeraisAges 18–60 - NCT05127226RecruitingPhase 1/Phase 2
Test drug safety for Angelman syndrome in young children
This early-phase study tests a new experimental medicine called ION582 to see if it is safe, tolerable, and how the body processes it in people with Angelman syndrome. It may also look at early signs of how the medicine affects the brain and body, which could guide future treatments.
San Diego, CaliforniaAges birth–50 years - NCT05199688RecruitingPhase 3
Satralizumab for children with AQP4-positive NMOSD attacks
This trial studies satralizumab in children ages 2 to 11 with a specific type of NMOSD caused by AQP4 antibodies. It aims to see how well the medicine prevents attacks and is safe over time.
Denver, ColoradoAges 2–11
Hear when a new Pharmacodynamics trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for pharmacodynamics?
- Yes. Clin2 currently lists 166 recruiting pharmacodynamics studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a pharmacodynamics trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a pharmacodynamics trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.